JPRN-UMIN000002929已完成未知
pilot study of systemic combination therapy with TS-1 and IFN for hepatocellular carcinoma patients with extrahepatic metastases who do not response to systemic combination therapy with TS-1 and cisplatin. - TS-1/IFN for HCC patients with metastases who do not response to TS-1/CDDP
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical, Hiroshima University0 个研究点目标入组 10 人开始时间: 2009年12月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) With other malignant disease. 2) A pregnant woman, or a woman suspected of pregnancy. 3) With severe infectious disease. 4) With history of severe allergy. 5) With severe renal function disease. 6) With severe allergy for 5FU, TS-1 or IFN. 7) With severe bone marrow supression. 8) With pulmonary fibrosis. 9) With another fluoropyrimidine 10)With flucytosine 9) with shosaikoto 10) with autoimmune hepatitis
研究者
相似试验
进行中（未招募）
不适用
Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levelsPatients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)MedDRA version: 12.0Level: LLTClassification code 10002198Term: Anaphylactic reactionMedDRA version: 12.0Level: LLTClassification code 10040400Term: Serum sicknessMedDRA version: 12.0Level: LLTClassification code 10043554Term: ThrombocytopeniaMedDRA version: 12.0Level: LLTClassification code 10019211Term: HeadacheMedDRA version: 12.0Level: LLTClassification code 10028810Term: NasopharyngitisMedDRA version: 12.0Level: LLTClassification code 10040753Term: SinusitisMedDRA version: 12.0Level: LLTClassification code 10022000Term: InfluenzaMedDRA version: 12.0Level: LLTClassification code 10006451Term: BronchitisMedDRA version: 12.0Level: LLTClassification code 10017888Term: GastroenteritisMedDRA version: 12.0Level: LLTClassification code 10034835Term: PharyngitisMedDRA version: 12.0Level: LLTClassification code 10047461Term: Viral infectionMedDRA version: 12.0Level: LLTClassification code 10034844Term: Pharyngolaryngeal painMedDRA version: 12.0Level: LLTClassification code 10011224Term: CoughMedDRA version: 12.0Level: LLTClassification code 10039083Term: RhinitisMedDRA version: 12.0Level: LLTClassification code 10028735Term: Nasal congestionMedDRA version: 12.0Level: LLTClassification code 10039085Term: Rhinitis allergicMedDRA version: 12.0Level: LLTClassification code 10012727Term: DiarrheaMedDRA version: 12.0Level: LLTClassification code 10028813Term: NauseaMedDRA version: 12.0Level: LLTClassification code 10013946Term: DyspepsiaMedDRA version: 12.0Level: LLTClassification code 10003988Term: Back painMedDRA version: 12.0Level: LLTClassification code 10003239Term: ArthralgiaMedDRA version: 12.0Level: LLTClassification code 10028411Term:EUCTR2009-014582-51-DEFaculty of Medicine, Technische Universität München
尚未招募
不适用
Observational study on the combined Treatment of Traditional Chinese and Western medicine for coronary heart disease after PCIITMCTR2100004449The First Affiliated Hospital of Henan University of CM
招募中
不适用
Clinical investigation of combination therapy with a1 blocker and vibegron for treating overactive bladder in patients with benign prostatic hyperplasiaoveractive bladderJPRN-UMIN000039150Koto Hospital, Dept. of Urology50
未知
3 期
Clinical investigation for combination therapy of KAD-1229 and Pioglitazone.Type 2 diabetesJPRN-jRCT2080220136KISSEI PHARMACEUTICAL CO.,LTD.
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30